Form RW - Registration Withdrawal Request
06 Giugno 2024 - 4:58PM
Edgar (US Regulatory)
FIBROBIOLOGICS,
INC.
455
E. Medical Center Blvd.
Suite
300
Houston,
Texas 77598
June
6, 2024
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
D.C. 20549
|
RE: |
FibroBiologics,
Inc. |
|
|
Request
to Withdraw Registration Statement on Form S-1 |
|
|
File
No. 333-278938 |
Ladies
and Gentlemen:
Pursuant
to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), FibroBiologics, Inc. (the “Company”)
hereby respectfully requests that the Company’s Registration Statement on Form S-1 (File No. 333-278938), as amended, together
with all exhibits thereto (the “Registration Statement”), initially filed with the Securities and Exchange Commission (the
“Commission”) on April 26, 2024, be withdrawn, effective as of the date hereof. The reason for such withdrawal is that the
Company has determined not to pursue the public offering to which the Registration Statement relates and will consider other alternatives.
The Registration Statement has not been declared effective by the Commission, and no securities have been issued or sold under the Registration
Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors,
as contemplated by paragraph (a) of Rule 477.
The
Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the
filing of the Registration Statement be credited for future use.
Pursuant
to Rule 477(c) under the Securities Act, the Company advises the Commission that it may, upon consideration of its financing needs and
options, undertake one or more subsequent private offerings in reliance on Rule 155(c) under the Securities Act.
Pursuant
to Rule 477(b), the Company understands that this request to withdraw the Registration Statement will be deemed granted as of the date
hereof unless the Company receives notice from the Commission within 15 days of the date hereof that such request will not be granted.
Thank you for your assistance and cooperation in this matter.
|
Very
truly yours, |
|
|
|
FibroBiologics,
Inc. |
|
|
|
|
By: |
/s/
Pete O’Heeron |
|
Name:
|
Pete
O’Heeron |
|
Title:
|
Chief
Executive Officer |
Grafico Azioni FibroBiologics (NASDAQ:FBLG)
Storico
Da Mar 2025 a Mar 2025
Grafico Azioni FibroBiologics (NASDAQ:FBLG)
Storico
Da Mar 2024 a Mar 2025